Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Equity (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Return on Equity for 6 consecutive years, with 0.28% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 3.0% to 0.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.28%, a 3.0% increase, with the full-year FY2025 number at 0.29%, up 14.0% from a year prior.
  • Return on Equity was 0.28% for Q4 2025 at Kymera Therapeutics, up from 0.35% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.08% in Q4 2021 to a low of 0.45% in Q3 2023.
  • A 5-year average of 0.28% and a median of 0.29% in 2024 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 35bps in 2021; the steepest drop was -59bps in 2021.
  • Kymera Therapeutics' Return on Equity stood at 0.08% in 2021, then tumbled by -300bps to 0.32% in 2022, then tumbled by -30bps to 0.42% in 2023, then increased by 28bps to 0.3% in 2024, then rose by 9bps to 0.28% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Return on Equity are 0.28% (Q4 2025), 0.35% (Q3 2025), and 0.36% (Q2 2025).